Physicians' Academy for Cardiovascular Education

SGLT2i

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

SGLT2i reduces risk of kidney and CV outcomes across subgroups of baseline UACR

News - Oct. 4, 2021

EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.

Wide distribution of 10-year and lifetime CV risk in patients with diabetes

News - Oct. 1, 2021

EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.

GLP-1RAs reduce HbA1c, body weight and SBP regardless of background SGLT2i use

News - Sep. 29, 2021

EASD 2021 HbA1c, body weight and SBP were lowered by semaglutide and liraglutide, regardless of background SGLT2i therapy in diabetes patients, in a post hoc analysis of SUSTAIN 6.

FDA Breakthrough Therapy Designation for SGLT2i in HFpEF

News - Sep. 14, 2021

The FDA has granted Breakthrough Therapy Designation to empagliflozin as an investigational treatment for patients with HFpEF, following the results from the EMPEROR-Preserved trial.

SGLT2 inhibitor reduces epicardial adipose tissue in nondiabetic patients with HFrEF

Literature - Sep. 13, 2021 - Requena-Ibáñez JA et al. - JACC Heart Fail. 2021

Empagliflozin significantly reduced epicardial adipose tissue, subcutaneous adipose tissue, myocardial extracellular volume, matrix volume, cardiomyocyte volume, aortic stiffness and several inflammatory biomarkers, compared to placebo in nondiabetic patients with HFrEF.

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD
Prof. Anker talks about the rationale, design, results and implications of the EMPEROR-Preserved trial which investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients with HFpEF.

ESC 2021 Prof. Anker talks about the rationale, design, results and implications of the EMPEROR-Preserved trial which investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients with HFpEF.

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD
After prof. Ruschitzka summarizes the EMPEROR-Preserved trial, he calls on us to reconsider our vision on dichotimizing HF by a threshold of EF.

ESC 2021 After prof. Ruschitzka summarizes the EMPEROR-Preserved trial, he calls on us to reconsider our vision on dichotimizing HF by a threshold of EF.

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD
In the EMPEROR-Pooled analysis, the efffect of empagliflozin on kidney and HF outcomes was assessed across the full spectrum of ejection fraction in HF. Prof. De Boer talks about the exciting findings.

ESC 2021 In the EMPEROR-Pooled analysis, the efffect of empagliflozin on kidney and HF outcomes was assessed across the full spectrum of ejection fraction in HF. Prof. De Boer talks about the exciting findings.

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD
Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.

ESC 2021 Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.

HF hospitalizations reduced by SGLT2 inhibitor across broad range of ejection fractions

News - Aug. 27, 2021

ESC 2021 EMPEROR-Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, compared to placebo, reduced HF hospitalizations by ~30% in patients with HF across a range of LVEF from <25% to <65%.

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD
Prof. de Boer gives an overview of the journey of SGLT2 inhibitors throughout the last years, from anti-diabetes drugs to demonstrated effectiveness in HFpEF.

ESC 2021 Prof. de Boer gives an overview of the journey of SGLT2 inhibitors throughout the last years, from anti-diabetes drugs to demonstrated effectiveness in HFpEF.

SGLT2i reduces composite of CV death or HF hospitalizations in HFpEF

News - Aug. 27, 2021

ESC 2021 The EMPEROR-Preserved trial showed that empagliflozin significantly reduced the risk of the primary composite endpoint of CV death or HF hospitalization by 21%, compared to placebo, in patients with HF and LVEF >40%, with and without T2DM.